Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog

This post hoc analysis of REVIEW showed that eptinezumab treatment can provide patient-perceived benefits across a spectrum of individuals with CM, including those with psychiatric comorbidities, in real-world settings. A greater number of good days regardless of number of prior mAb therapy supports the use of eptinezumab earlier for individuals with CM, rather than cycling through multiple anti-CGRP therapies. Furthermore, good days can provide a meaningful and measurable endpoint to assess preventive treatment and is correlated with improvements in brain fog.

Authors

Institutions

Publication Details

Journal
The Journal of Headache and Pain
Published
2025-11-27
DOI
https://doi.org/10.1186/s10194-025-02165-2
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog

Divya Asher, Ryan M. Smith, Charles E. Argoff, Fawad Khan et al.
The Journal of Headache and Pain
Migraine and Headache Studies
article

Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog

Divya Asher, Ryan M. Smith, Charles E. Argoff, Fawad Khan, Susanne F. Awad, Foram Patel, Seema Soni-Brahmbhatt, Sharon R. Grossman, Steven Herzog, Dawn C. Buse
article en

Abstract

This post hoc analysis of REVIEW showed that eptinezumab treatment can provide patient-perceived benefits across a spectrum of individuals with CM, including those with psychiatric comorbidities, in real-world settings. A greater number of good days regardless of number of prior mAb therapy supports the use of eptinezumab earlier for individuals with CM, rather than cycling through multiple anti-CGRP therapies. Furthermore, good days can provide a meaningful and measurable endpoint to assess preventive treatment and is correlated with improvements in brain fog.

The Journal of Headache and PainVol. 26(1)
Albert Einstein College of Medicine (US), Lundbeck (Denmark) (DK), Ochsner Health System (US), Saint Luke's Health System (US), The University of Queensland (AU), Deerfield (United States) (US), Texas Neurology (US), Lundbeck (United States) (US), Albany Medical Center Hospital (US)
H. Lundbeck A/S
Openalex Percentile: Top 57%
Migraine and Headache Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog — Divya Asher, Ryan M. Smith, et al. · The Journal of Headache and Pain (2025) | TGRS Research Map | TGRS